Regenxbio (RGNX) reported Monday a 97% reduction in anti-VEGF injections at nine months in a Phase II study of ABBV-RGX-314 for wet age-related macular degeneration, or AMD.

In the subretinal treatment of the second eye, 78% of patients remained injection-free, the company said. Visual acuity and retinal thickness were maintained, with no serious drug-related adverse events observed, it added.

The study is evaluating ABBV-RGX-314 as a potential one-time gene therapy to address the burden of lifelong injections in wet AMD, according to the company statement.

Shares of Regenxbio were up more than 4% in recent pre-market trading.

Price: 11.55, Change: +0.45, Percent Change: +4.05